靶向Xklp2靶蛋白在胆管癌组织中的表达及其临床意义
| 作者: |
1郑兵兵,
1付晓伟,
1陈海敏,
1杜鹏程,
1张军,
1胡双辉,
2熊美雪,
1方路
1 南昌大学第二附属医院 肝胆胰外科，江西 南昌 330006 2 江西省共青城市人民医院 普通外科，江西 共青城 332020 |
| 通讯: |
方路
Email: fanglu@medmail.com.cn |
| DOI: | 10.3978/.2018.02.011 |
| 基金: | 江西省科技厅重点基金资助项目（20171BBG70063）；江西省卫计委基金资助项目（20175202）；江西省南昌大学研究生创新基金资助项目（cx2016329）。 |
摘要
目的：探讨在胆管癌组织中靶向Xklp2靶蛋白（TPX2）的表达及其临床意义。
方法：收集60例胆管癌患者的癌组织及癌旁组织标本，用免疫组化方法检测TPX2蛋白的阳性表达率，随机抽取4对标本用Western blot方法检测TPX2蛋白的表达量；分析癌组织中TPX2蛋白的表达与患者临床病理参数及预后之间的关系。
结果：胆管癌癌组织中TPX2蛋白的阳性表达率（46.7% vs. 8.3%，P<0.05）及表达量West blot均高于癌旁组织。TPX2蛋白的表达与患者TNM分期、淋巴结转移以及生存有关（均P<0.05）；TPX2蛋白阳性患者的术后生存率明显低于其阴性患者（2年生存率：27.6% vs. 78.4%；3年生存率：14.3% vs. 59.5%，均P<0.05）。
结论：TPX2高表达可能是胆管癌患者术后发生转移、复发的危险因素；TPX2可能是评价胆管癌早期诊断和预后一个潜在生物学指标和治疗的潜在靶点。
关键词：
胆管肿瘤；微管相关蛋白质类；肿瘤侵润；预后
方法：收集60例胆管癌患者的癌组织及癌旁组织标本，用免疫组化方法检测TPX2蛋白的阳性表达率，随机抽取4对标本用Western blot方法检测TPX2蛋白的表达量；分析癌组织中TPX2蛋白的表达与患者临床病理参数及预后之间的关系。
结果：胆管癌癌组织中TPX2蛋白的阳性表达率（46.7% vs. 8.3%，P<0.05）及表达量West blot均高于癌旁组织。TPX2蛋白的表达与患者TNM分期、淋巴结转移以及生存有关（均P<0.05）；TPX2蛋白阳性患者的术后生存率明显低于其阴性患者（2年生存率：27.6% vs. 78.4%；3年生存率：14.3% vs. 59.5%，均P<0.05）。
结论：TPX2高表达可能是胆管癌患者术后发生转移、复发的危险因素；TPX2可能是评价胆管癌早期诊断和预后一个潜在生物学指标和治疗的潜在靶点。
Expression of targeting protein for xenopus kinesin-like protein 2 in cholangiocarcinoma and its clinical significance
CorrespondingAuthor:FANG Lu Email: fanglu@medmail.com.cn
Abstract
Objective: To investigate the expression of targeting protein for xenopus kinesin-like protein 2 (TPX2) in cholangiocarcinoma tissue and its clinical significance.
Methods: The cancer tissues together with their adjacent tissues from 60 patients with cholangiocarcinoma were collected. The positive expression rates of TPX2 protein in these tissues were determined by immunohistochemical staining, and the TPX2 protein expression levels were detected by Western blot in 4 pairs of randomly selected tissues. The relations of TPX2 protein expression with the clinical factors and prognosis of the patients were analyzed.
Results: In cholangiocarcinoma tissue compared with adjacent tissue, the positive expression rate (46.7% vs. 8.3%, P<0.05) and expression level of TPX2 protein were increased. The TPX2 protein expression was significantly associated with the TNM stage, lymph node metastasis and survival of the patients (all P<0.05). The postoperative survival rates in patients with positive TPX2 protein expression were significantly lower than those in patients with its negative expression (2-year survival rate: 27.6% vs. 78.4%; 3-year survival rate: 14.3% vs. 59.5%, both P<0.05).
Conclusion: High TPX2 expression may possibly be associated with postoperative recurrence and metastasis in cholangiocarcinoma patients. It may be a potential biological indicator for the early diagnosis and estimation of prognosis and a therapeutic target of cholangiocarcinoma.
Keywords：
Bile Duct Neoplasms; Microtubule-Associated Proteins; Neoplasm Invasiveness; Prognosis
Methods: The cancer tissues together with their adjacent tissues from 60 patients with cholangiocarcinoma were collected. The positive expression rates of TPX2 protein in these tissues were determined by immunohistochemical staining, and the TPX2 protein expression levels were detected by Western blot in 4 pairs of randomly selected tissues. The relations of TPX2 protein expression with the clinical factors and prognosis of the patients were analyzed.
Results: In cholangiocarcinoma tissue compared with adjacent tissue, the positive expression rate (46.7% vs. 8.3%, P<0.05) and expression level of TPX2 protein were increased. The TPX2 protein expression was significantly associated with the TNM stage, lymph node metastasis and survival of the patients (all P<0.05). The postoperative survival rates in patients with positive TPX2 protein expression were significantly lower than those in patients with its negative expression (2-year survival rate: 27.6% vs. 78.4%; 3-year survival rate: 14.3% vs. 59.5%, both P<0.05).
Conclusion: High TPX2 expression may possibly be associated with postoperative recurrence and metastasis in cholangiocarcinoma patients. It may be a potential biological indicator for the early diagnosis and estimation of prognosis and a therapeutic target of cholangiocarcinoma.